Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK/ChemoCentryx Crohn’s Failure May Sink Hefty Phase III Program

This article was originally published in The Pink Sheet Daily

Executive Summary

SHIELD-1 failure puts the entire 2,500-patient plus Phase III clinical program in limbo as GSK rethinks its Crohn’s disease approach and partner ChemoCentryx’s stock loses close to half its value.

Advertisement

Related Content

Deals Of The Week Watches An Unlikely HCIT Partnership: GSK & Community Care of North Carolina
ChemoCentryx Regains Crohn’s Candidate Vercirnon From GSK
ViiV Secures Its First New Drug Approval With Tivicay
GSK Is Getting Ready For A Return To The ’90s
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS076148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel